Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib-first versus TNF inhibitor-first treat-to-target strategy in rheumatoid arthritis
NL-OMON20976Recruiting
- Sponsor
- prof. dr. M.A.F.J. van de Laar
- Start
- Mar 2019
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, open-label trial of baricitinib in rheumatoid arthritis (RA) (2 arms), sponsored by prof. dr. M.A.F.J. van de Laar. Primary endpoint: ACR50 response at 12 weeks. Started Mar 2019; status: recruiting.
02
Drugs
baricitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON20976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20976.